Pezzi Hannah M, Berry Scott M, Beebe David J, Striker Rob
Department of Biomedical Engineering, Wisconsin Institutes for Medical Research, University of Wisconsin-Madison, 1111 Highland Avenue, Madison, Wisconsin 53705, USA.
Integr Biol (Camb). 2017 Nov 13;9(11):876-884. doi: 10.1039/c7ib00112f.
Quantification of the HIV viral reservoir is critical to understanding HIV latency, advancing patient care and ultimately achieving a cure. To quantify the reservoir, a new metric was recently introduced, which quantified cells carrying multiply spliced HIV RNA. The developed assay, Tat/rev Induced Limiting Dilution Assay (TILDA), enables quantification of cells containing multiply-spliced HIV RNA events as an indicator of reservoir size. Due to TILDA's reliance on a limiting dilution format paired with the rarity of target events, numerous individual reactions are required to obtain a single endpoint. The current assay embodiment uses a whole cell input to detect target RNA sequences without the traditional preceding nucleic acid purification steps. Thus, while the direct measurement of target events from whole cells significantly streamlines the workflow, there is a cost in sensitivity and assay throughput. Here, we apply a new technique for rapid RNA isolation, Exclusion-Based Sample Preparation, to TILDA, with the goal of alleviating these limitations without significantly adding to the workflow. By combining TILDA with multiplexed RNA extraction enabled by exclusion-based sample preparation, assay sensitivity and capacity are improved while maintaining assay simplicity, advancements that could facilitate eventual clinical implementation in detecting rare events in patients.
对HIV病毒储存库进行定量对于理解HIV潜伏状态、改善患者护理并最终实现治愈至关重要。为了对储存库进行定量,最近引入了一种新的指标,该指标对携带多重剪接HIV RNA的细胞进行定量。所开发的检测方法,即Tat/rev诱导极限稀释分析(TILDA),能够对含有多重剪接HIV RNA事件的细胞进行定量,以此作为储存库大小的指标。由于TILDA依赖极限稀释形式且目标事件罕见,需要进行大量的个体反应才能获得单个终点。当前的检测方法采用全细胞输入来检测目标RNA序列,而无需传统的核酸纯化前处理步骤。因此,虽然从全细胞直接测量目标事件显著简化了工作流程,但在灵敏度和检测通量方面存在代价。在此,我们将一种新的快速RNA分离技术,即基于排除的样品制备技术,应用于TILDA,目的是在不显著增加工作流程的情况下减轻这些限制。通过将TILDA与基于排除的样品制备实现的多重RNA提取相结合,在保持检测简单性的同时提高了检测灵敏度和能力,这些进展有助于最终在临床中检测患者中的罕见事件。